HLN (Haleon) Moat Score: 6/10 (As of Jul. 07, 2026)


HLN Haleon PLC HLN
70 GF Score
Price $9.72
GF Value $9.87
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Haleon Moat Score?

Haleon HLN -1.02% 70 Moat Score is 6 as of Jul. 07, 2026. GuruFocus rates HLN with a GF Score™ of 70/100 and a GF Value™ of $9.87 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,032 Drug Manufacturers companies, Haleon ranks better than 97.09% on this metric.

Haleon has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Haleon has Narrow Moat: Haleon PLC benefits from strong brand strength and customer loyalty in consumer healthcare. It has a solid distribution network and some pricing power, but lacks significant regulatory barriers or exclusive licenses. Its moat is supported by economies of scale and a robust product portfolio, but not enough to be considered wide.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Haleon might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Haleon  (NYSE:HLN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Haleon Moat Score Related Terms

HLN vs ZTS, UTHR, VTRS: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Haleon's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Haleon Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Haleon's Moat Score distribution charts can be found below:

* The bar in red indicates where Haleon's Moat Score falls into.


HLN
70GF Score
Haleon PLC HLN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Haleon (HLN) has a Moat Score of 6 as of Jul. 07, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Haleon ranks #30 out of 1032 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Haleon's Moat Score too high?
Haleon's current Moat Score is 6. Based on the distribution chart, Haleon ranks #30 out of 1032 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Haleon has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Haleon's Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Haleon ranks #30 out of 1032 companies for Moat Score. This places Haleon in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Haleon's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleon stock overvalued right now?
Based on GuruFocus' analysis, Haleon (HLN) is currently considered Fairly Valued. The stock's GF Value™ is $9.87, compared to a current price of $9.72 — trading 1.5% below its estimated fair value. The current Moat Score is 6. Haleon's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Haleon (HLN), the current Moat Score is 6 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haleon (HLN) Overvalued in 2026?

Based on GuruFocus' analysis, Haleon stock appears to be undervalued. The current stock price of $9.72 is trading 1.5% below its estimated GF Value™ of $9.87. GuruFocus considers Haleon to be Fairly Valued.

Key valuation signals for HLN:

  • Moat Score: 6
  • GF Value™: $9.87 vs. price of $9.72 (1.5% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the HLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haleon Business Description

Address The Heights, Building 5, First Floor, Weybridge, Surrey, GBR, KT13 0NY
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
70GF Score

Get the complete analysis for HLN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.72
Price
$9.87
GF Value